SOURCE: Eurand N.V.

Eurand N.V.

February 04, 2010 08:00 ET

Eurand Announces Conference Call on Fourth Quarter and Full-Year 2009 Financial Results

AMSTERDAM, THE NETHERLANDS--(Marketwire - February 4, 2010) - Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Thursday, March 4, 2010 at 8:30 a.m. ET to discuss its fourth quarter and full-year 2009 financial results. The conference call will be hosted by Gearóid Faherty, Chairman and Chief Executive Officer, and Mario Crovetto, Chief Financial Officer.

The conference call schedule is as follows:

7:00 a.m. ET: Release of fourth quarter and full-year 2009 financial

8:20 a.m. ET: Dial in to participate in the conference call:

              -- U.S. Participants dial 1-877-407-9039
              -- International Participants dial +1-201-689-8470

8:30 a.m. ET: Conference call begins

Call Replay: A replay of the call will be available from 11:30 a.m. ET on
March 4, 2010 until April 4, 2010.  The Account Number is: 3055; Conference
ID Number: 343839.

              -- U.S. Participants dial 1-877-660-6853
              -- International Participants dial +1-201-612-7415

Webcast: A live webcast of the call also will be available from the Investor Relations section of the corporate web site at Following the live webcast, the archived version of the call will be available at the same URL until April 4, 2010.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at

Contact Information